Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FENCNASDAQ:ITOSNASDAQ:PROKNASDAQ:RGNX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFENCFennec Pharmaceuticals$6.27+5.4%$5.92$3.96▼$10.07$164.18M0.32105,246 shs78,283 shsITOSiTeos Therapeutics$6.92+3.9%$6.55$4.80▼$18.70$264.86M1.39471,864 shs1.00 million shsPROKProKidney$0.75+4.0%$0.84$0.46▼$4.44$219.52M1.5691,348 shs622,271 shsRGNXREGENXBIO$7.97+6.0%$7.36$5.04▼$16.85$399.43M1.11850,257 shs1.12 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFENCFennec Pharmaceuticals0.00%-5.24%+19.16%-10.49%-38.77%ITOSiTeos Therapeutics0.00%-14.03%+18.23%-6.96%-61.70%PROKProKidney0.00%-8.59%-1.35%-54.63%-74.33%RGNXREGENXBIO0.00%-27.69%+27.67%-4.69%-51.30%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFENCFennec Pharmaceuticals1.7337 of 5 stars3.61.00.00.01.72.50.0ITOSiTeos Therapeutics2.4743 of 5 stars3.51.00.00.03.62.50.6PROKProKidney2.1983 of 5 stars3.30.00.00.02.64.20.6RGNXREGENXBIO4.1146 of 5 stars3.41.00.04.63.42.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFENCFennec Pharmaceuticals 3.25Buy$13.67117.97% UpsideITOSiTeos Therapeutics 3.00Buy$25.50268.50% UpsidePROKProKidney 2.50Moderate Buy$5.00566.67% UpsideRGNXREGENXBIO 2.83Moderate Buy$31.63296.80% UpsideCurrent Analyst Ratings BreakdownLatest FENC, RGNX, PROK, and ITOS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/29/2025ITOSiTeos TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$17.00 ➝ $16.004/17/2025RGNXREGENXBIOThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$14.00 ➝ $12.003/20/2025RGNXREGENXBIOChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$52.00 ➝ $52.003/18/2025RGNXREGENXBIOLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$24.003/17/2025RGNXREGENXBIOHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$36.00 ➝ $34.003/14/2025RGNXREGENXBIOMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$22.00 ➝ $24.003/14/2025RGNXREGENXBIOChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$52.00 ➝ $52.003/11/2025FENCFennec PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.003/10/2025FENCFennec PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$13.003/6/2025ITOSiTeos TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$19.00 ➝ $17.003/6/2025ITOSiTeos TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$22.00 ➝ $15.00(Data available from 5/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFENCFennec Pharmaceuticals$47.54M3.64N/AN/A($0.43) per share-14.58ITOSiTeos Therapeutics$35M7.57N/AN/A$16.08 per share0.43PROKProKidney$76K2,888.47N/AN/A($4.84) per share-0.15RGNXREGENXBIO$83.33M4.79N/AN/A$7.09 per share1.12Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFENCFennec Pharmaceuticals-$16.05M-$0.06N/AN/AN/A-2.30%-53.38%-2.08%5/13/2025 (Estimated)ITOSiTeos Therapeutics-$112.64M-$3.04N/AN/AN/AN/A-20.11%-17.50%N/APROKProKidney-$35.47M-$0.63N/AN/AN/AN/AN/A-10.24%N/ARGNXREGENXBIO-$263.49M-$4.61N/AN/AN/A-283.19%-70.65%-41.68%5/14/2025 (Estimated)Latest FENC, RGNX, PROK, and ITOS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025RGNXREGENXBIO$0.35$0.12-$0.23$0.12$105.35 millionN/A5/13/2025Q1 2025FENCFennec Pharmaceuticals-$0.12N/AN/AN/A$8.18 millionN/A5/9/2025Q1 2025PROKProKidney-$0.16-$0.13+$0.03-$0.13N/AN/A4/28/2025Q1 2025ITOSiTeos Therapeutics-$0.94-$0.80+$0.14-$0.80$9.35 millionN/A3/17/2025Q4 2024PROKProKidney-$0.14-$0.17-$0.03-$0.17N/A$0.08 million3/13/2025Q4 2024RGNXREGENXBIO-$1.27-$1.01+$0.26-$1.01$23.70 million$21.21 million3/5/2025Q4 2024ITOSiTeos Therapeutics-$1.14-$1.01+$0.13-$1.01N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFENCFennec PharmaceuticalsN/AN/AN/AN/AN/AITOSiTeos TherapeuticsN/AN/AN/AN/AN/APROKProKidneyN/AN/AN/AN/AN/ARGNXREGENXBION/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFENCFennec PharmaceuticalsN/A7.807.64ITOSiTeos TherapeuticsN/A14.8014.80PROKProKidneyN/A17.0817.09RGNXREGENXBION/A3.053.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFENCFennec Pharmaceuticals55.51%ITOSiTeos Therapeutics97.16%PROKProKidney51.59%RGNXREGENXBIO88.08%Insider OwnershipCompanyInsider OwnershipFENCFennec Pharmaceuticals11.76%ITOSiTeos Therapeutics12.50%PROKProKidney41.49%RGNXREGENXBIO12.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFENCFennec PharmaceuticalsN/A27.59 million24.54 millionOptionableITOSiTeos Therapeutics9038.27 million31.97 millionOptionablePROKProKidney3292.70 million170.65 millionOptionableRGNXREGENXBIO37050.12 million43.04 millionOptionableFENC, RGNX, PROK, and ITOS HeadlinesRecent News About These CompaniesRegenxbio (RGNX) Q1 Earnings and Revenues Lag EstimatesMay 12 at 6:30 PM | zacks.comREGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational HighlightsMay 12 at 4:05 PM | prnewswire.comBalyasny Asset Management L.P. Has $9.18 Million Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX)May 12 at 4:33 AM | marketbeat.comREGENXBIO Inc. (NASDAQ:RGNX) Given Average Rating of "Moderate Buy" by BrokeragesMay 12 at 2:51 AM | marketbeat.comRaymond James Financial Inc. Takes Position in REGENXBIO Inc. (NASDAQ:RGNX)May 11 at 3:30 AM | marketbeat.comStifel Financial Corp Buys 39,564 Shares of REGENXBIO Inc. (NASDAQ:RGNX)May 10 at 3:45 AM | marketbeat.com5RGNX : What to Expect from Regenxbio's EarningsMay 9 at 9:41 PM | benzinga.comREGENXBIO (RGNX) Projected to Post Quarterly Earnings on WednesdayMay 9 at 8:19 AM | marketbeat.comREGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual MeetingMay 8, 2025 | prnewswire.comHsbc Holdings PLC Acquires 48,310 Shares of REGENXBIO Inc. (NASDAQ:RGNX)May 8, 2025 | marketbeat.comREGENXBIO to Participate in Upcoming Investor ConferencesMay 6, 2025 | prnewswire.comREGENXBIO Inc. (NASDAQ:RGNX) Shares Sold by Invesco Ltd.May 6, 2025 | marketbeat.comRegenxbio (RGNX) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseMay 5, 2025 | zacks.comPDT Partners LLC Makes New Investment in REGENXBIO Inc. (NASDAQ:RGNX)May 4, 2025 | marketbeat.comREGENXBIO Inc. (NASDAQ:RGNX) Shares Sold by CANADA LIFE ASSURANCE CoMay 3, 2025 | marketbeat.comLegal & General Group Plc Lowers Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX)May 3, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Buys Shares of 500,000 REGENXBIO Inc. (NASDAQ:RGNX)May 2, 2025 | marketbeat.comREGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational HighlightsApril 30, 2025 | prnewswire.comRegenxbio Stock Short Interest Report | NASDAQ:RGNX | BenzingaApril 29, 2025 | benzinga.comRenaissance Technologies LLC Takes $2.10 Million Position in REGENXBIO Inc. (NASDAQ:RGNX)April 28, 2025 | marketbeat.comQuantessence Capital LLC Takes $270,000 Position in REGENXBIO Inc. (NASDAQ:RGNX)April 25, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFENC, RGNX, PROK, and ITOS Company DescriptionsFennec Pharmaceuticals NASDAQ:FENC$6.27 +0.32 (+5.38%) Closing price 04:00 PM EasternExtended Trading$6.26 -0.01 (-0.16%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.iTeos Therapeutics NASDAQ:ITOS$6.92 +0.26 (+3.90%) Closing price 04:00 PM EasternExtended Trading$7.06 +0.15 (+2.10%) As of 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.ProKidney NASDAQ:PROK$0.75 +0.03 (+3.96%) Closing price 04:00 PM EasternExtended Trading$0.80 +0.05 (+6.13%) As of 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.REGENXBIO NASDAQ:RGNX$7.97 +0.45 (+5.98%) Closing price 04:00 PM EasternExtended Trading$7.88 -0.09 (-1.07%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
